T-817ma (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 149 | Hemiconvulsion hemiplegia epilepsy syndrome | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-194633 | 05/6/2019 | 15/02/2019 | A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study of T-817MA in Post-stroke Patients Undergoing Rehabilitation for Upper Limb Hemiplegia | A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study of T-817MA in Post-stroke Patients Undergoing Rehabilitation for Upper Limb Hemiplegia | Patients with upper limb hemiplegia after cerebral infarction or cerebral hemorrhage (other than subarachnoid hemorrhage) | Intervention name : T-817MA INN of the intervention : Edonerpic Dosage And administration of the intervention : Oral Multiple Dose Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - | FUJIFILM Toyama Chemical Co., Ltd | NULL | recruiting | 20 | 84 | BOTH | 65 | Phase 2 | Japan |